If you go to any meetings on precision medicine, you’ll have noticed the increasing amount of interest in artificial intelligence (AI).
Scientists have successfully created a biohybrid robot that has the potential to carry drugs to specific parts of the body, minimising side effects.
Although DNA-home testing is getting a lot more accessible for the everyday person, Senator Chuck Schumer claims doing so is more dangerous than we think.
AstraZeneca has revealed plans to take part in a new drug development joint venture with a state-backed private equity fund.
If you have been keeping tabs on the website this week, then you’ll be aware at just how much of a booming year biotech companies are having.
The FDA has warned that it will be coming down hard on anyone carrying out do-it-yourself gene therapy, in a recent statement.
One under the radar biotech could be trumping all its competitors, after it makes significant progress in potentially producing an Alzheimer’s treatment.
This Thanksgiving investors are thankful that the S&P 500 is up about 15% year to date, with that path expected to continue to the end of the year.
The three big players in the world of cloud computing released their quarterly earnings this week, and it’s clear who’s speeding ahead.
The FDA has released new guidelines in a bid to quicken the implementation of treatments involving human cells and tissues, including gene therapy.
Josiah Zayner, the scientist who left NASA to bring genetic engineering to consumers has modified his own genome with CRISPR (true DIY style).
With more money being plugged into battling antibiotic resistance, researchers have begun to consider synthetic biology as a new way to fight bacteria.